Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
A new study breaks down several cases of Ozempic blindness, linked to semaglutide and tirzepatide. Here's what could be behind this.
The risk of pharma bribery, the risk of brain drain, and other risks (and rewards) in the biotech landscape this week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback